Del Mar Pharmaceuticals

OverviewSuggest Edit

DelMar Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The Сompany’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. DelMar Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. 
TypePublic
Founded2010
HQSan Diego, US
Websitedelmarpharma.com
Culture scoreD

Latest Updates

Employees (est.) (Jun 2019)2(-50%)
Revenue (FY, 2012)$0
Share Price (May 2020)$1 (-4%)

Key People/Management at Del Mar Pharmaceuticals

Saiid Zarrabian

Saiid Zarrabian

President and Chief Executive Officer, Director
Dennis M. Brown

Dennis M. Brown

Chief Scientific Officer
Scott Praill

Scott Praill

CFO
Lynda Cranston

Lynda Cranston

Director
Robert E. Hoffman

Robert E. Hoffman

Chairman of the Board
Robert J. Toth

Robert J. Toth

Director
Show more

Del Mar Pharmaceuticals Office Locations

Del Mar Pharmaceuticals has offices in San Diego and Menlo Park
San Diego, US (HQ)
12707 High Bluff Dr #200
Menlo Park, US
3475 Edison Way r
Show all (2)

Del Mar Pharmaceuticals Financials and Metrics

Del Mar Pharmaceuticals Revenue

USD

Net income (Q3, 2020)

(2.0m)

Market capitalization (29-May-2020)

11.2m

Closing stock price (29-May-2020)

1.0

Cash (31-Mar-2020)

5.0m
Del Mar Pharmaceuticals's current market capitalization is $11.2 m.
Annual
USDFY, 2012FY, 2015FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

7.3k3.3m

R&D expense

5.0m

Operating expense total

7.3k8.3m33.2k60.7k
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

General and administrative expense

696.04.2k1.4k4.2k920.4k1.7m741.4k445.0k656.2k500.8k474.0k890.7k630.2k1.3m571.3k698.1k744.6k1.0m1.2m986.5k874.9k935.5k913.6k1.1m1.1m

R&D expense

631.9k584.4k560.2k671.6k612.2k641.8k603.8k789.2k790.3k732.7k1.1m1.1m1.9m2.1m1.8m1.0m947.2k735.8k721.5k712.2k898.7k

Operating expense total

696.04.2k1.4k4.2k1.6m2.2m1.3m1.1m1.3m1.1m1.1m1.7m1.4m2.0m1.7m1.8m2.7m3.2m2.9m2.0m1.8m1.7m1.7m1.8m2.0m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.8k4.1m4.8m1.8m6.6m6.0m3.7m

Accounts Receivable

11.1k

Prepaid Expenses

170.9k234.6k245.0k1.2m1.0m

Current Assets

7.9m7.0m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

6.8k805.02.8k609.04.0k7.5m6.3m5.2m3.5m4.0m3.0m2.8m2.0m937.4k4.8m3.4m2.1m13.2m11.0m8.5m3.9m3.7m2.2m8.1m6.3m5.0m

Accounts Receivable

Prepaid Expenses

83.5k221.3k210.5k269.6k155.9k357.6k191.6k167.5k85.3k177.3k130.8k119.8k1.2m1.1m1.1m831.5k306.7k240.1k223.7k123.0k114.9k

Current Assets

3.4m3.0m2.1m1.1m5.0m3.6m2.3m14.4m12.2m9.6m4.7m4.0m2.4m8.4m6.5m5.1m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.9k)(8.3m)(2.8m)(4.3m)(8.9m)8.1m(11.1m)(8.0m)

Depreciation and Amortization

10.3k16.7k24.5k16.3k

Accounts Payable

2.5k(537.2k)104.4k517.4k(178.3k)598.3k295.8k202.0k

Cash From Operating Activities

(11.4k)(5.5m)(1.9m)(3.9m)(5.1m)(8.0m)(9.9m)(6.3m)
USDY, 2020

Financial Leverage

1.4 x
Show all financial metrics

Del Mar Pharmaceuticals Online and Social Media Presence

Embed Graph

Del Mar Pharmaceuticals Company Culture

  • Overall Culture

    D

    59/100

  • CEO Rating

    D

    63/100

  • Compensation

    C+

    70/100

Learn more on Comparably

Del Mar Pharmaceuticals Blogs

DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020

SAN DIEGO, Feb. 5, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Mr. Saiid Zarrabian, Chief Executive Officer of DelMar will attend the 2…

DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

February Issue of "Glioma" Highlights Positive Progression-Free Survival Data SAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announc…

DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019

SAN DIEGO, Dec. 3, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that Mr. Saiid Zarrabian, Chief Executive Officer of DelMar, will be a featured pre…

DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM

Newly-Diagnosed Patients Showing Promising Progression-Free Survival Compared to TMZ Historical Data Recurrent Patients Showing Promising Overall Survival Compared to Lomustine Historical Data SAN DIEGO, Nov. 25, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "C…

DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates

SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the quarter ended September 30, 2019. "Following a productive quarte…

DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083

Renowned Experts from Multiple Key GBM Cancer Centers, Including M.D. Anderson Cancer Center and Sun Yat-sen Cancer Center to Provide Insight on Treatment Modalities SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutica…
Show more

Del Mar Pharmaceuticals Frequently Asked Questions

  • When was Del Mar Pharmaceuticals founded?

    Del Mar Pharmaceuticals was founded in 2010.

  • Who are Del Mar Pharmaceuticals key executives?

    Del Mar Pharmaceuticals's key executives are Saiid Zarrabian, Dennis M. Brown and Scott Praill.

  • How many employees does Del Mar Pharmaceuticals have?

    Del Mar Pharmaceuticals has 2 employees.

  • Who are Del Mar Pharmaceuticals competitors?

    Competitors of Del Mar Pharmaceuticals include Klus Pharma, Iovance Biotherapeutics and Spectrum Pharmaceuticals.

  • Where is Del Mar Pharmaceuticals headquarters?

    Del Mar Pharmaceuticals headquarters is located at 12707 High Bluff Dr #200, San Diego.

  • Where are Del Mar Pharmaceuticals offices?

    Del Mar Pharmaceuticals has offices in San Diego and Menlo Park.

  • How many offices does Del Mar Pharmaceuticals have?

    Del Mar Pharmaceuticals has 2 offices.